Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
HAE
Haemonetics Corporation
Haemonetics manufactures medical devices and biometrics for hospital blood management and plasma processing.
|
$3.48B |
$72.12
-2.54%
|
|
IPGP
IPG Photonics Corporation
IPG markets medical laser systems including thulium lasers for urology, fitting Medical Devices & Biometrics.
|
$3.45B |
$81.79
+2.20%
|
|
LIVN
LivaNova PLC
Directly manufactures/distributes Neuromodulation Devices, including VNS Therapy and proximal hypoglossal nerve stimulation systems.
|
$3.39B |
$62.13
-1.68%
|
|
AMED
Amedisys, Inc.
Direct provision of Home Health and Hospice services across multiple centers.
|
$3.31B |
$100.99
|
|
VCYT
Veracyte, Inc.
The company offers MRD and other liquid biopsy tests, placing it in the liquid biopsy space.
|
$3.27B |
$41.61
+1.49%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$3.27B |
$37.90
-2.29%
|
|
PBH
Prestige Consumer Healthcare Inc.
Clear Eyes is an ophthalmic over-the-counter product, fitting Ophthalmic Drugs.
|
$3.20B |
$65.12
-0.75%
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$3.20B |
$36.63
-0.95%
|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$3.16B |
$31.29
-2.39%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$3.14B |
$35.83
-0.64%
|
|
WGS
GeneDx Holdings Corp.
Clinical lab chains providing genetic testing services.
|
$3.10B |
$107.89
-1.27%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.10B |
$25.86
-1.92%
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$3.08B |
$40.02
-1.77%
|
|
TNET
TriNet Group, Inc.
Health Insurance as TriNet provides employee group health benefits to client workforces.
|
$3.05B |
$62.71
-0.79%
|
|
SXI
Standex International Corporation
Medical devices & biometrics/public healthcare equipment segment exposure.
|
$3.02B |
$249.97
-0.27%
|
|
ITGR
Integer Holdings Corporation
Integer is a contract development and manufacturing organization (CDMO) for medical devices, directly providing design, development and manufacturing services to OEMs.
|
$3.01B |
$85.77
+0.57%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$3.00B |
$71.15
-3.39%
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$2.98B |
$22.14
-1.18%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$2.97B |
$46.55
+0.59%
|
|
ATS
ATS Corporation
ATS-related offerings intersect with Medical Devices & Biometrics via automated production of regulated devices.
|
$2.96B |
$30.65
+0.43%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$2.92B |
$39.42
+3.96%
|
|
BKD
Brookdale Senior Living Inc.
Brookdale provides healthcare services and facilities through its senior living communities, including care delivery and facility management.
|
$2.90B |
$12.20
+8.44%
|
|
EWTX
Edgewise Therapeutics, Inc.
Edgewise's lead programs sevasemten and EDG-7500 are orally administered small-molecule therapeutics, i.e., an oral small molecule therapeutics platform.
|
$2.89B |
$27.41
+3.06%
|
|
PRVA
Privia Health Group, Inc.
Privia provides physician enablement, MSO and value-based care services, i.e., Healthcare Services & Facilities.
|
$2.86B |
$23.34
-2.18%
|
|
LFST
LifeStance Health Group, Inc.
Direct provider of behavioral health outpatient services (therapy, psychiatric evaluations, care coordination).
|
$2.82B |
$7.26
-2.42%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.80B |
$50.04
-0.44%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$2.78B |
$22.71
-1.09%
|
|
CON
Concentra Group Holdings Parent, Inc.
Concentra operates a nationwide network of outpatient occupational health centers and onsite employer clinics, i.e., outpatient/ASC operations.
|
$2.76B |
$21.55
-0.14%
|
|
INSP
Inspire Medical Systems, Inc.
Inspire V is a neuromodulation device designed to treat obstructive sleep apnea, representing Inspire's core product category.
|
$2.73B |
$92.24
-4.38%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.72B |
$33.23
+0.62%
|
|
BBU
Brookfield Business Partners L.P.
Healthscope operates hospital services, a healthcare services/ facilities business.
|
$2.67B |
$36.22
-0.28%
|
|
ADPT
Adaptive Biotechnologies Corporation
ADPT directly provides clonoSEQ MRD diagnostic testing and related laboratory services.
|
$2.67B |
$17.51
-1.52%
|
Showing page 9 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
